Phase I trial of dihydroxyanthracenedione

D. A. Van Echo, M. Y. Whitacre, J. Aisner, P. H. Wiernick

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Dihydroxyanthracenedione was given to 16 patients with solid tumors in a phase I clinical trial. The dose schedule used was a single daily dose for 3 consecutive days given every 3 weeks. The amount given ranged from 2 to 5 mg/m2/day. The dose-limiting toxic effect was moderate to severe leukopenia which occurred at a dose ≥ 4 mg/m2/day x 3. Thrombocytopenia was infrequent and did not require transfusion. Nonhematologic side effects were insignificant and included nausea, vomiting, and green-tinged urine. A minor tumor response was noted in a patient with fibrosarcoma. The recommended doses for solid tumor phase II studies are 4 mg/m2/day x 3 for good-risk patients and 3 mg/m2/day x 3 for poor-risk patients, given every 3 weeks.

Original languageEnglish (US)
Pages (from-to)831-834
Number of pages4
JournalCancer treatment reports
Volume65
Issue number9-10
StatePublished - Jan 1 1981
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I trial of dihydroxyanthracenedione'. Together they form a unique fingerprint.

  • Cite this

    Van Echo, D. A., Whitacre, M. Y., Aisner, J., & Wiernick, P. H. (1981). Phase I trial of dihydroxyanthracenedione. Cancer treatment reports, 65(9-10), 831-834.